MENU
EDIT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Editas Medicine (EDIT) Earnings Date & Reports

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

EDIT is expected to report earnings to rise 22.93% to -18 cents per share on February 25

Editas Medicine EDIT Stock Earnings Reports
Q4'26
Est.
$-0.18
Q3'26
Beat
by $0.06
Q2'26
Beat
by $0.12
Q1'26
Beat
by $0.01
Q4'25
Beat
by $0.17
The last earnings report on November 09 showed earnings per share of -15 cents, beating the estimate of -20 cents. With 304.65K shares outstanding, the current market capitalization sits at 394.70M.
A.I.Advisor
Nov 09, 2026

Editas Medicine (EDIT) Q3 2026 Earnings Recap: Revenue Surge Meets Pipeline Hopes

Key Takeaways

  • Editas Medicine (EDIT) reported a third-quarter 2026 net loss of $0.15 per share, beating the consensus estimate of a $0.19 loss.
  • Revenue came in at $10.37 million, far above analyst expectations of roughly $4.5 million, driven by milestone payments from its Bristol Myers Squibb collaboration.
  • Results improved markedly versus the year-ago quarter, when the company posted a $0.28 per-share loss on $7.54 million in revenue.
  • The company remains a pre-clinical gene-editing player with no approved products, keeping investor focus on its in vivo (inside the body) pipeline, led by the EDIT-401 program targeting LDL cholesterol (low-density lipoprotein, or "bad" cholesterol).
  • You can find more details on Major News, Today's Price Move, Price Targets, and Forecast on additional Tickeron pages.
  • For automated trade ideas and market insights, explore Trending AI Robots.

Earnings Context and Why It Matters

Editas Medicine's quarterly results carry outsized weight because the company is navigating a strategic transition. After ending its reni-cel program in late 2024, Editas returned to a pre-clinical stage and refocused its resources on in vivo gene editing. With no approved products yet, collaboration revenue and pipeline execution are the primary drivers of investor confidence. The third-quarter beat, powered by Bristol Myers Squibb milestone payments, offers evidence that Editas can fund its research through partnerships while it advances EDIT-401 toward the clinic. For investors, the report is a checkpoint on both near-term cash generation and the credibility of a longer-term gene-editing thesis.

Reported Results

For the third quarter of 2026, Editas Medicine reported a net loss of $0.15 per share, which was narrower than the $0.19 per share loss Wall Street had projected. Revenue of $10.37 million substantially exceeded the consensus estimate of approximately $4.5 million. Both figures improved from the year-ago period, when the company recorded a $0.28 per-share loss on $7.54 million in revenue.

The top-line outperformance was primarily attributable to milestone revenue recognized under the company's collaboration agreement with Bristol Myers Squibb. Operating expenses remained a key focus, reflecting the leaner cost structure Editas adopted after its prior strategic reprioritization. The results reinforced a pattern of collaboration-driven revenue visibility even as the company continues to invest in its emerging in vivo pipeline.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to streamline your research workflow, consider exploring the AI Screener to uncover actionable market insights.

Market Reaction and Investor Sentiment

Editas shares have shown volatility in 2026, reflecting a tug-of-war between optimism over pipeline milestones and lingering concerns about a pre-clinical company that has yet to generate product revenue. Heading into the report, analyst sentiment was mixed, with expectations for continued losses offset by confidence in the company's collaboration income and its extended cash runway. The clear top-line and bottom-line beat highlights the importance of Bristol Myers Squibb milestones as a revenue bridge, but investor interpretation will ultimately hinge on whether the company can translate research progress into clinical catalysts rather than relying on one-time payments.

Forward Outlook and Key Factors to Monitor

Looking ahead, the primary catalyst is the clinical advancement of EDIT-401, Editas' lead in vivo gene-editing candidate designed to durably lower LDL cholesterol. Management has previously signaled plans to file an investigational new drug (IND) or clinical trial application by mid-2026, with initial human proof-of-concept data targeted for late 2026. Investors should watch closely whether these timelines hold, as any slippage could weigh on sentiment.

Capital efficiency remains another key factor. Because Editas has no approved products, its cash position and runway will determine how far the pipeline can advance before additional financing is needed. The company's collaboration agreement with Bristol Myers Squibb provides milestone-driven revenue, but such payments are inherently lumpy and difficult to model quarter to quarter.

Finally, monitor broader dynamics in the gene-editing sector, including competitive progress from peers and regulatory developments. A balanced view should weigh Editas' promising in vivo approach against the execution and funding risks inherent in early-stage biotechnology.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
87
Web
https://www.editasmedicine.com